canertinib has been researched along with Squamous Cell Carcinoma of Head and Neck in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ju, WT; Liang, SY; Tang, X; Zhang, ZY; Zhao, TC; Zhong, LP; Zhou, ZH; Zhu, DW | 1 |
1 other study(ies) available for canertinib and Squamous Cell Carcinoma of Head and Neck
| Article | Year |
|---|---|
Mechanism of sensitivity to cisplatin, docetaxel, and 5-fluorouracil chemoagents and potential erbB2 alternatives in oral cancer with growth differentiation factor 15 overexpression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cisplatin; Fluorouracil; Growth Differentiation Factor 15; Humans; Mice; Morpholines; Mouth Neoplasms; Phosphorylation; Receptor, ErbB-2; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Taxoids | 2022 |